SciELO - Scientific Electronic Library Online

 
vol.28 issue4Changing Paradigms in PsychiatrySCHIZOPHRENIA, SENSE AND NONSENSE author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Psiquiatría

Print version ISSN 0034-7450

Abstract

LEON, Javier et al. SERTRALINE IN OBSESSIVE COMPULSIVE DISORDER. AN OPEN, MULTICENTRIC, NON-COMPARATIVE STUDY. rev.colomb.psiquiatr. [online]. 1999, vol.28, n.4, pp.323-333. ISSN 0034-7450.

In order to evalúate the efficacy and safety of a fixed dose of Sertraline in the management of outpatients with Obsessive-Compulsive Disorder (OCD) with or without Major Depression comorbidity, an open, multicenter, non comparative study was conducted. Six Colombian centers included 52 Hispanic subjects, between 18 and 65 years old, mainly females (65%). The period of treatment was 16 to 32 weeks with 50 or 200 mg fixed dose. The subjects responded in similar proportion to the Sertraline treatment for OCD with or without Major Depression comorbidity. In the 52 initial subjects with 50 mg fixed dose, Y-BOCS scale improvedin average, 44% at 8a week, and, 63% at 16a week (p<0.001). GCI severity, GCI improvement and HAM-D followed the same tendency (p <0.001). Eightsubjects underwentan increase ofthe daily dose up to 200 mg. Twenty-one subjects reportad adverse events, headache (15%) and nausea (12%) were the most common. In conclusión, fixed dose of 50 mg of Sertraline was effective for improving the OCD in the majority of subjects (85%), 200 mg was also effective. Sertraline was well tolerated and the safety was similar as other studies.

Keywords : Obsessive-Compulsive-Disorder; Sertraline; Depression; Y-BOCS; Colombia.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License